🇺🇸 FDA
Patent

US 11291657

Methods of treating inflammatory bowel disease with AMD3100 and Tacrolimus

granted A61KA61K31/00A61K31/365

Quick answer

US patent 11291657 (Methods of treating inflammatory bowel disease with AMD3100 and Tacrolimus) held by MedRegen, LLC expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MedRegen, LLC
Grant date
Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/00, A61K31/365, A61K31/395, A61K31/436